Collapsin Response-Mediator Protein-5-IgG, Western Blot, Serum
Use
Autoantibodies specific for neurons and muscle are important serological markers of neurological autoimmunity. CRMP-5 is highly expressed in small-cell lung carcinomas, neurons, and a subset of glial cells. CRMP-5-IgG, known as anti-CV-2, often accompanies SCLC and sometimes occurs with thymomas. It can present multifocally in patients, affecting various levels of the neuraxis and is associated with neurological syndromes suggesting CRMP-5-IgG relevance.
Special Instructions
It is recommended that an evaluation be ordered alongside this test if not previously done. Multiple neurological phenotype-specific autoimmune/paraneoplastic evaluations are available. For more information, refer to the Autoimmune Neurology Test Ordering Guide. Provide relevant clinical information and healthcare professional details (name, phone, address, email) when requesting the test.
Limitations
CRMP-5-IgG may not be detectable by standard IF screening if titers are low or if coexisting autoantibodies impede identification. Seronegativity does not exclude the presence of a neoplasm. Western blot analysis is advised if interfering autoantibodies prevent accurate detection of CRMP-5-IgG by indirect immunofluorescence assay.
New York Approved
Methodology
Immunoassay (Western Blot)
Biomarkers
LOINC Codes
- 47401-5
- 47401-5
Result Turnaround Time
5-10 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1.5 mL
Minimum Volume
1 mL
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Causes for Rejection
Gross hemolysis, Gross lipemia, Gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 28 days |
| Frozen | 28 days |